Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

40.80
+0.54001.34%
Pre-market: 41.801.00+2.45%08:46 EDT
Volume:1.75M
Turnover:70.95M
Market Cap:1.39B
PE:-6.31
High:41.14
Open:39.89
Low:39.01
Close:40.26
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:33.55M
Volume Ratio:0.60
T/O Rate:5.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.54
PE(LYR):-4.20

Loading ...

Nektar Therapeutics Initiated at Market Perform by Raymond James

Dow Jones
·
1 hour ago

Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)

Simply Wall St.
·
6 hours ago

Nektar initiated with a Market Perform at Raymond James

TIPRANKS
·
16 hours ago

B. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)

TIPRANKS
·
Oct 02

Nektar Therapeutics Price Target Maintained with a $185.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 02

Nektar selloff yesterday overdone, says H.C. Wainwright

TIPRANKS
·
Oct 02

Movement Alert|Nektar Therapeutics Falls 19.63% in Regular Trading, Trading at $48.81

Market Focus
·
Oct 02

Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says Jefferies

TIPRANKS
·
Oct 02

William Blair says rezpeg data a positive for Nektar

TIPRANKS
·
Oct 02

Nektar Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since February 2023

Dow Jones
·
Oct 02

Nektar falls -21.6%

TIPRANKS
·
Oct 02

Nektar Stock Sinks Despite Promising Hair Loss Treatment Data

Dow Jones
·
Oct 01

Nektar Says Phase 3 Zenith AD Trial for Rezpegaldesleukin Expands into Treatment-Experienced Patients

Reuters
·
Oct 01

Nektar Therapeutics - Rezpegaldesleukin Demonstrates Durability and Deepening of Response Through One Year of Treatment

THOMSON REUTERS
·
Oct 01

Nektar Therapeutics - Rezpegaldesleukin Safety Profile Through 52 Weeks Favorable and Consistent with Previous Reports

THOMSON REUTERS
·
Oct 01

Nektar Therapeutics - Phase 3 Zenith Aa Study to Initiate in Early 2027

THOMSON REUTERS
·
Oct 01

Nektar Therapeutics - Salt Score ≤20 Response Maintained in 75% at 4 Months, 63% at 6 Months Off Treatment

THOMSON REUTERS
·
Oct 01

Nektar Therapeutics Says Rezpegaldesleukin in Atopic Dermatitis Showed Improvements as Early as Week 2

MT Newswires Live
·
Oct 01

Nektar: Rezpegaldesleukin-associated improvements detected as early as Week 2

TIPRANKS
·
Sep 30

Nektar Says Rezpegaldesleukin Shows Early Biomarker Response in Phase 2b Rezolve-AD Atopic Dermatitis Study

Reuters
·
Sep 30